SPC231
Ertuglíflosín, valkvætt sem kristalform, einkum sem samkristall með L-pýróglútamínsýru, og sérstaklega sem ertuglíflosín L-pýróglútamínsýra
Status:
VeittApplication date:
14.8.2018Application published:
15.9.2018Grant published:
15.9.2021
Max expiry date:
22.3.2033Medicine name:
SteglatroMedicine for children:
No
Timeline
Today
14.8.2018Application
15.9.2018Publication
15.9.2021Registration
22.3.2033Expires
Marketing license
IS authorization number:
EU/1/18/1267/001-006; EU/1/18/1267/007-012Date:
10.4.2018
Foreign authorization number:
EU/1/18/1267Date:
21.3.2018
Owner
Name:
Pfizer Inc.Address:
66 Hudson Boulevard East, New York, NY 10001-2192 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2334687